Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
October 24, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
October 11, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
October 10, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
October 02, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
September 21, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
September 07, 2023 07:03 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023

Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy NEW...
September 05, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at Three Upcoming Investor Conferences

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
August 07, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Total 2Q 2023 product revenue of $46.7 million Auvelity® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth Sunosi® 2Q 2023 net product revenue...
July 12, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right